Understanding the Market | XUANZHUBIO-B rises over 5% again as the company presents clinical phase III research data on palbociclib for breast cancer at the ESMO annual meeting
I'm PortAI, I can summarize articles.
XUANZHUBIO-B's stock price rose over 5% again, with an increase of 5.12% as of the time of writing, reported at HKD 62.65, with a transaction volume of HKD 23.5573 million. The company presented clinical phase III research data on the combination of palbociclib with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer at the 2025 European Society for Medical Oncology (ESMO). Based on the interim data from this study, the National Medical Products Administration of China accepted the new drug application on May 14, 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments